ANXA1 and diabetes mellitus: AnxA1 has been shown to afford protection in murine diabetic nephropathy by decreasing p38, ERK and JNK, and activating Akt signaling, suggesting that AnxA1 could be a potential therapeutic strategy for treating renal dysfunction caused by diseases such as diabetes [79].